Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| The Global Immuno-oncology Therapeutics Market--Checkpoint Inhibitors | ||
| By: PR Newswire Association LLC. - 29 Sep 2016 | Back to overview list |
|
LONDON, Sept. 29, 2016 /PRNewswire/ -- The Next Generation of Cancer Therapies Market Snapshot Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to tumor growth and progression. Checkpoint Inhibitor Market: Market Snapshot, Global, 2015 Checkpoint pathways constitute the "checks and balances" segment of the immune system which facilitates the recognition of foreign substances or tumor cells by the T-cells. Approximately 245 companies globally are developing therapies in the checkpoint inhibitor area, with over xx% in the United States. GLOBOCAN reported in 20xxan estimated 14.1 million new cases of cancer per year, with the projected incidence to rise to xx million by the year 20xx The overall checkpoint inhibitor market is over $xx billion and is set to grow at a CAGR of xx% (20xx–20xx. - Although the US dominates the market, because of the exorbitant drug development investments, new opportunities do exist in Europe and Japan where cancer incidence is increasing. - Analysts have estimated the potential of the total immuno-oncology market peak sales to be worth $xx to $xx billion by 20xx with more product approvals and indication expansions for existing products. Download the full report: https://www.reportbuyer.com/product/4000248/ SOURCE ReportBuyer 
|
||
|
|
||
 | Back to overview list | |